LifeSci Capital initiated coverage of Protara Therapeutics (TARA) with an Outperform rating and $22 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics’ TARA-002 Shows Promising Efficacy and Safety in HR-NMIBC, Earning Buy Rating
- Protara Therapeutics Reports Progress and Financial Results
- Protara Therapeutics reports Q4 EPS (48c) vs (90c) last year
- TARA Earnings this Week: How Will it Perform?
- Protara Therapeutics Outlines 2025 Milestones After Fundraising